Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases

Integr Cancer Ther
December 2009
https://pubmed.ncbi.nlm.nih.gov/20042414/

The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol

Integr Cancer Ther
March 2006
https://www.ncbi.nlm.nih.gov/pubmed/16484716

Low-dose Naltrexone Targets the Opioid Growth Factor-Opioid Growth Factor Receptor Pathway to Inhibit Cell Proliferation: Mechanistic Evidence From a Tissue

Exp Biol Med (Maywood)
September 2011
https://pubmed.ncbi.nlm.nih.gov/21807817/

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.